InSphero celebrated our 10 year anniversary in 2019. Looking back over the past decade, I’m grateful to have had the chance to drive and shape the 3D cell-based assay revolution and spur innovation in 3D in vitro technology. Rather than wax nostalgic by listing all our innovation milestones since 2009, I’d like to share some of our key news stories from this year to get you thinking about how we can partner in 2020 to further advance drug discovery and safety testing.
If you’re interested in exploring partnership opportunities with us to leverage our award-winning 3D biology platforms and unique research perspective on drug discovery and safety testing, let’s talk in 2020. Look for me and our team at the JP Morgan Healthcare Conference, SLAS, or SOT.
Hope you have a wonderful holiday break.
Jan Lichtenberg, PhD
InSphero CEO and Co-founder
Watch this video to learn how we applied our scalable Akura™ technology and 10 years of experience in perfecting 3D in vitro human liver models to develop the first automation-compatible 3D in vitro human liver disease platform for NAFLD and NASH.